Efgartigimod as rescue treatment in acute phase of neuromyelitis optica spectrum disorder: A Case Report

作者全名：Li, Zhizhong; Xu, Qiao; Huang, Jialu; Zhu, Qiyuan; Yang, Xiaolin; Zhang, Mengjie; Zhang, Shaoru; Huang, Siyuan; Yu, Gang; Zheng, Peng; Qin, Xinyue; Feng, Jinzhou

作者地址：[Li, Zhizhong; Xu, Qiao; Yang, Xiaolin; Zhang, Mengjie; Zhang, Shaoru; Huang, Siyuan; Yu, Gang; Zheng, Peng; Qin, Xinyue; Feng, Jinzhou] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China; [Huang, Jialu] 958th Hosp Peoples Liberat Army, Chongqing 400038, Peoples R China; [Zhu, Qiyuan] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China

通信作者：Qin, XY; Feng, JZ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China.

来源：HELIYON

ESI学科分类：　

WOS号：WOS:001235971200001

JCR分区：Q1

影响因子：3.4

年份：2024

卷号：10

期号：9

开始页：　

结束页：　

文献类型：Article

关键词：Neuromyelitis optica spectrum disorder; (NMOSD); Efgartigimod; AQP4-IgG; FcRn. case report

摘要：Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a central nervous system demyelinating disease. Current therapy methods, however, have limited effect on acute attacks except for intravenous methylprednisolone (IVMP). Efgartigimod is a first -in -class novel human immunoglobulin G1 (IgG1) Fc fragment approved for the treatment of generalized myasthenia gravis. Its capacity to rapidly decrease serum IgG levels, including pathogenic autoantibodies, positions it as a potentially effective option for managing the acute phase of NMOSD. Case presentation: We report the case of a 59 -year -old female patient with acute NMOSD, presenting with vision loss and numbness in all four limbs. Despite an initial inadequate response to intravenous methylprednisolone (IVMP), the addition of Efgartigimod to her treatment regimen led to rapid improvement, notably including a significant reduction in serum aquaporin-4 antibody titers, total IgG levels, and inflammation cytokine levels. Furthermore, no adverse events were reported during a four -month follow-up period. Conclusion: As an adjunct to glucocorticoid therapy, Efgartigimod has proven effective and safe for this patient. However, to ascertain its potential as a novel therapeutic option for acute NMOSD, larger -scale prospective clinical trials are required.

基金机构：　

基金资助正文：